Payden & Rygel’s Gilead Sciences GILD Stock Holding History

Payden & Rygel’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.7M	Hold	91,280	–	–	0.98%	47
2025 Q4	$11.2M	Hold	91,280	–	–	0.77%	47
2025 Q3	$10.1M	Buy	91,280 +22,900	+33%	+$2.6M	0.84%	55
2025 Q2	$7.58M	Buy	68,380 +68,200	+37,889%	+$7.26M	0.63%	65
2025 Q1	$20K	Hold	180	–	–	﹤0.01%	124
2024 Q4	$17K	Hold	180	–	–	﹤0.01%	123
2024 Q3	$15K	Hold	180	–	–	﹤0.01%	121
2024 Q2	$12K	Sell	180 -2,500	-93%	-$167K	﹤0.01%	121
2024 Q1	$196K	Hold	2,680	–	–	0.01%	119
2023 Q4	$217K	Hold	2,680	–	–	0.02%	119
2023 Q3	$201K	Hold	2,680	–	–	0.01%	119
2023 Q2	$207K	Sell	2,680 -8,720	-76%	-$695K	0.01%	121
2023 Q1	$946K	Hold	11,400	–	–	0.06%	102
2022 Q4	$979K	Hold	11,400	–	–	0.05%	102
2022 Q3	$703K	Hold	11,400	–	–	0.04%	102
2022 Q2	$705K	Hold	11,400	–	–	0.04%	101
2022 Q1	$678K	Sell	11,400 -290,300	-96%	-$18.6M	0.03%	99
2021 Q4	$21.9M	Buy	+301,700	New	+$20.8M	1.01%	55
2021 Q1	–	Sell	-1,400	Closed	-$82K	–	135
2020 Q4	$82K	Hold	1,400	–	–	﹤0.01%	121
2020 Q3	$88K	Sell	1,400 -19,400	-93%	-$1.35M	0.01%	107
2020 Q2	$1.6M	Hold	20,800	–	–	0.1%	68
2020 Q1	$1.55M	Buy	20,800 +1,200	+6%	+$82.9K	0.11%	65
2019 Q4	$1.27M	Sell	19,600 -3,200	-14%	-$208K	0.08%	64
2019 Q3	$1.45M	Hold	22,800	–	–	0.1%	61
2019 Q2	$1.54M	Hold	22,800	–	–	0.11%	65
2019 Q1	$1.48M	Sell	22,800 -250,200	-92%	-$16.6M	0.11%	67
2018 Q4	$17.1M	Buy	273,000 +18,200	+7%	+$1.27M	1.38%	32
2018 Q3	$19.7M	Buy	254,800 +3,200	+1%	+$242K	1.5%	29
2018 Q2	$17.8M	Hold	251,600	–	–	1.4%	36
2018 Q1	$19M	Hold	251,600	–	–	1.54%	26
2017 Q4	$18M	Buy	251,600 +500	+0.2%	+$38K	1.56%	26
2017 Q3	$20.3M	Buy	251,100 +249,700	+17,836%	+$19.1M	2.02%	13
2017 Q2	$99K	Hold	1,400	–	–	0.01%	85
2017 Q1	$95K	Hold	1,400	–	–	0.01%	87
2016 Q4	$100K	Hold	1,400	–	–	0.01%	85
2016 Q3	$111K	Hold	1,400	–	–	0.01%	75
2016 Q2	$117K	Hold	1,400	–	–	0.01%	76
2016 Q1	$129K	Hold	1,400	–	–	0.02%	75
2015 Q4	$142K	Hold	1,400	–	–	0.02%	80
2015 Q3	$137K	Hold	1,400	–	–	0.02%	81
2015 Q2	$164K	Hold	1,400	–	–	0.02%	81
2015 Q1	$137K	Hold	1,400	–	–	0.02%	85
2014 Q4	$132K	Hold	1,400	–	–	0.03%	79
2014 Q3	$149K	Sell	1,400 -600	-30%	-$58.8K	0.03%	79
2014 Q2	$166K	Hold	2,000	–	–	0.04%	80
2014 Q1	$142K	Hold	2,000	–	–	0.06%	78
2013 Q4	$150K	Hold	2,000	–	–	0.05%	103
2013 Q3	$126K	Hold	2,000	–	–	0.04%	101
2013 Q2	$103K	Buy	+2,000	New	+$104K	0.04%	108

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Payden & Rygel's GILD Position: Q1 2026 in Review

Payden & Rygel held its Gilead Sciences (GILD) position steady in Q1 2026 at 91,280 shares worth $12.7M. The position accounts for 0.98% of the portfolio, ranked #47.

Payden & Rygel first reported a position in GILD in Q2 2013 and has held it in 49 quarters since. The position peaked at $21.9M in Q4 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Payden & Rygel held 91,280 shares of Gilead Sciences worth $12.7M as of Q1 2026.
Payden & Rygel left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.98% of Payden & Rygel's portfolio in Q1 2026, its #47 holding.
Payden & Rygel first reported a position in Gilead Sciences in Q2 2013 and has held it in 49 quarters since.
Payden & Rygel's Gilead Sciences position peaked at $21.9M in Q4 2021.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.